BELBUCA utilizes BDSI's patented BioErodible
MucoAdhesive drug delivery technology to deliver buprenorphine, which is a Schedule III medicine.
DOSE Medical is developing multiple micro-invasive, bioerodible
, sustained-release drug delivery platforms designed to be used in the treatment of various retinal diseases, including age-related macular degeneration and diabetic macular edema.
BDSI is utilising its novel and proprietary BioErodible
MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.
Greiner, "Electrospinning and cutting of ultrafine bioerodible
poly(lactideco-ethylene oxide) tri- and multiblock copolymer fibers for inhalation applications," Polymers for Advanced Technologies, vol.
Development of a novel bioerodible
dexamethasone implant for uveitis and postoperative cataract inflammation.
An investigator-sponsored clinical trial is ongoing for an injectable, bioerodible
microinsert to treat glaucoma and ocular hypertension, a product candidate on which Pfizer Inc.
The composition is bioerodible
, not a denture adhesive, and substantially free of polybutene with a molecular weight of approximately 300-3000 when the composition is not an article, and is applied to dentures.
The drug uses BDSI's patented BioErodible
MucoAdhesive (BEMA) technology to deliver the opioid analgesic buprenorphine.
Baker, Theory and practice of controlled drug delivery from bioerodible
polymers, in Controlled Release of Bioactive Materials, (Ed) R.
MucoAdhesive (BEMA) delivery system is designed to deliver either local or systemic levels of drugs across mucosal tissues.
Lux will access the technology, the expertise, and the state of the art infrastructure at the Center to develop bioerodible
, polymers capable of eluting drug molecules as a platform for ophthalmic drug products.